40/120
1.7 / 5 stars
All 120 Win/Lose results shown below
JNJ Roast Me summary
JOHNSON & JOHNSON (JNJ). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseJNJ / S&P 4.50% / 15.20% |
LoseJNJ / S&P 8.06% / 15.00% |
LoseJNJ / S&P -7.81% / 50.40% |
| 2026-Q11/3 |
WinJNJ / S&P 18.74% / -4.33% |
LoseJNJ / S&P 7.87% / 11.30% |
LoseJNJ / S&P -3.89% / 27.70% |
| 2025-Q42/3 |
WinJNJ / S&P 12.32% / 2.65% |
LoseJNJ / S&P 6.05% / 9.00% |
WinJNJ / S&P 90.50% / 13.40% |
| 2025-Q33/3 |
WinJNJ / S&P 22.28% / 8.12% |
WinJNJ / S&P 5.08% / 4.61% |
WinJNJ / S&P 68.46% / 13.45% |
| 2025-Q20/3 |
LoseJNJ / S&P -7.10% / 10.94% |
LoseJNJ / S&P 4.68% / 4.83% |
LoseJNJ / S&P -38.69% / 10.63% |
| 2025-Q11/3 |
WinJNJ / S&P 15.59% / -4.27% |
LoseJNJ / S&P 4.30% / 4.98% |
LoseJNJ / S&P -41.16% / 10.57% |
| 2024-Q40/3 |
LoseJNJ / S&P -10.05% / 2.41% |
LoseJNJ / S&P 4.30% / 5.25% |
LoseJNJ / S&P -57.80% / 6.15% |
| 2024-Q31/3 |
WinJNJ / S&P 11.72% / 5.89% |
LoseJNJ / S&P 4.77% / 5.89% |
LoseJNJ / S&P -54.31% / 6.11% |
| 2024-Q21/3 |
LoseJNJ / S&P -6.86% / 4.28% |
LoseJNJ / S&P 5.13% / 5.38% |
WinJNJ / S&P 209.33% / 5.12% |
| 2024-Q11/3 |
LoseJNJ / S&P 1.69% / 10.56% |
LoseJNJ / S&P 0.94% / 5.71% |
WinJNJ / S&P 220.34% / 5.59% |
| 2023-Q41/3 |
LoseJNJ / S&P 1.44% / 11.69% |
LoseJNJ / S&P 6.46% / 6.81% |
WinJNJ / S&P 103.86% / 7.78% |
| 2023-Q32/3 |
LoseJNJ / S&P -5.22% / -3.27% |
WinJNJ / S&P 8.41% / 7.52% |
WinJNJ / S&P 87.47% / -5.03% |
| 2023-Q20/3 |
LoseJNJ / S&P 7.59% / 8.74% |
LoseJNJ / S&P 2.23% / 9.50% |
LoseJNJ / S&P -28.24% / -8.57% |
| 2023-Q10/3 |
LoseJNJ / S&P -11.62% / 7.50% |
LoseJNJ / S&P 6.27% / 10.77% |
LoseJNJ / S&P -35.71% / -15.69% |
| 2022-Q42/3 |
WinJNJ / S&P 8.83% / 7.56% |
LoseJNJ / S&P 1.59% / 11.88% |
WinJNJ / S&P -13.83% / -17.99% |
| 2022-Q31/3 |
LoseJNJ / S&P -7.35% / -4.88% |
LoseJNJ / S&P -15.57% / 13.47% |
WinJNJ / S&P 7.32% / -1.41% |
| 2022-Q21/3 |
WinJNJ / S&P 0.80% / -16.10% |
LoseJNJ / S&P -9.68% / 13.71% |
LoseJNJ / S&P 3.31% / 11.04% |
| 2022-Q11/3 |
WinJNJ / S&P 4.27% / -4.60% |
LoseJNJ / S&P -5.19% / 15.97% |
LoseJNJ / S&P 31.10% / 42.23% |
| 2021-Q40/3 |
LoseJNJ / S&P 6.62% / 11.03% |
LoseJNJ / S&P -4.65% / 15.00% |
LoseJNJ / S&P 41.74% / 96.40% |
| 2021-Q31/3 |
LoseJNJ / S&P -1.38% / 0.58% |
WinJNJ / S&P 13.10% / 10.77% |
LoseJNJ / S&P 5.19% / 69.42% |
| 2021-Q21/3 |
LoseJNJ / S&P 0.86% / 8.55% |
WinJNJ / S&P 10.79% / 6.58% |
LoseJNJ / S&P 16.87% / 51.81% |
| 2021-Q11/3 |
LoseJNJ / S&P 5.08% / 6.17% |
WinJNJ / S&P 1.80% / -1.06% |
LoseJNJ / S&P -11.70% / 7.39% |
| 2020-Q42/3 |
LoseJNJ / S&P 6.44% / 12.15% |
WinJNJ / S&P 0.64% / -3.72% |
WinJNJ / S&P -2.13% / -33.42% |
| 2020-Q32/3 |
LoseJNJ / S&P 6.57% / 8.93% |
WinJNJ / S&P -1.04% / -2.04% |
WinJNJ / S&P 21.14% / -27.10% |
| 2020-Q21/3 |
LoseJNJ / S&P 7.99% / 20.54% |
LoseJNJ / S&P -1.01% / -0.46% |
WinJNJ / S&P -5.64% / -27.11% |
| 2020-Q12/3 |
WinJNJ / S&P -9.53% / -19.60% |
LoseJNJ / S&P 1.39% / 3.47% |
WinJNJ / S&P 18.70% / -14.75% |
| 2019-Q41/3 |
WinJNJ / S&P 13.53% / 9.07% |
LoseJNJ / S&P 0.59% / 5.36% |
LoseJNJ / S&P 0.36% / 2.99% |
| 2019-Q31/3 |
LoseJNJ / S&P -6.41% / 1.70% |
LoseJNJ / S&P 0.40% / 5.02% |
WinJNJ / S&P 789.83% / 0.21% |
| 2019-Q21/3 |
LoseJNJ / S&P 0.32% / 4.30% |
LoseJNJ / S&P 0.79% / 6.64% |
WinJNJ / S&P 1059.62% / 8.65% |
| 2019-Q11/3 |
LoseJNJ / S&P 9.04% / 13.65% |
LoseJNJ / S&P JNJ unavailable / 8.12% |
WinJNJ / S&P 1048.94% / 14.29% |
| 2018-Q42/3 |
WinJNJ / S&P -6.01% / -13.52% |
LoseJNJ / S&P 6.71% / 9.05% |
WinJNJ / S&P 1093.62% / 18.23% |
| 2018-Q31/3 |
WinJNJ / S&P 14.63% / 7.71% |
LoseJNJ / S&P JNJ unavailable / 10.21% |
LoseJNJ / S&P -89.76% / 19.06% |
| 2018-Q20/3 |
LoseJNJ / S&P -4.61% / 3.43% |
LoseJNJ / S&P JNJ unavailable / 9.03% |
LoseJNJ / S&P -91.22% / 14.46% |
| 2018-Q10/3 |
LoseJNJ / S&P -7.69% / -0.76% |
LoseJNJ / S&P JNJ unavailable / 7.68% |
LoseJNJ / S&P -92.10% / 12.46% |
| 2017-Q41/3 |
WinJNJ / S&P 8.13% / 6.64% |
LoseJNJ / S&P 6.34% / 7.03% |
LoseJNJ / S&P -92.07% / 13.82% |
| 2017-Q30/3 |
LoseJNJ / S&P -1.10% / 4.48% |
LoseJNJ / S&P JNJ unavailable / 5.68% |
LoseJNJ / S&P 1.05% / 17.57% |
| 2017-Q21/3 |
WinJNJ / S&P 6.92% / 3.09% |
LoseJNJ / S&P JNJ unavailable / 4.83% |
LoseJNJ / S&P 10.24% / 17.74% |
| 2017-Q11/3 |
WinJNJ / S&P 8.82% / 6.07% |
LoseJNJ / S&P JNJ unavailable / 3.67% |
LoseJNJ / S&P 7.21% / 13.32% |
| 2016-Q41/3 |
LoseJNJ / S&P -1.80% / 3.82% |
LoseJNJ / S&P JNJ unavailable / 2.09% |
WinJNJ / S&P 8.21% / 7.05% |
| 2016-Q31/3 |
LoseJNJ / S&P -1.96% / 3.85% |
LoseJNJ / S&P JNJ unavailable / 0.20% |
WinJNJ / S&P 8.99% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | JNJ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 54.69% | 20.78% |
| Annualized return | 54.69% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | JNJ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 77.39% | 83.14% |
| Annualized return | 12.15% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | JNJ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 195.41% | 319.30% |
| Annualized return | 11.44% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |